HAB Pharma to Expand Business with Two New Plants for Inhalers and Large-Volume Tablets
#HABPharmaceuticals #HABPharma #PharmaManufacturingThey are actively developing new molecules such as tofacitinib, posaconazole, and fixed-dose combinations of sitagliptin and dapagliflozin, alongside exploring advanced formulations like oral jelly for sildenafil and dapoxetine, aiming to enhance patient compliance and experience.
July 2024 : HAB Pharma announces expansion with two new plants—one for metered dose inhalers and another for large-volume tablets. These expansions demonstrate the company's dedication to meeting the increasing demands of the pharmaceutical market.
HAB Pharma’s commitment to innovation is evident in its significant investment in research and development. They are actively developing new molecules such as tofacitinib, posaconazole, and fixed-dose combinations of sitagliptin and dapagliflozin, alongside exploring advanced formulations like oral jelly for sildenafil and dapoxetine, aiming to enhance patient compliance and experience.
From its modest beginnings in Vasai to its current stature with state-of-the-art facilities, HAB Pharma continues to stand as a symbol of quality, innovation, and social responsibility in the pharmaceutical sector.
Founded in 1989 by KK Agrawal and Sanjiv Garg, HAB Pharmaceuticals and Research Ltd. embarked on its journey from a small factory in Vasai. Initially focusing on manufacturing tablets and capsules for the local market, especially in Mumbai, the founders aimed to provide high-quality medicines at affordable prices directly to local doctors. This approach quickly gained traction, earning trust and loyalty from medical professionals and leading to steady demand growth.
By 2001, HAB Pharma secured its first export order, marking a significant milestone in its expansion. A notable early achievement was its role in manufacturing sildenafil citrate, marketed under the brand name VEGA, which gained popularity in the Middle East and Africa. This move not only accelerated growth but also established HAB Pharma as a key player in the pharmaceutical industry. Collaborations, notably with Zydus Cadila, further fueled their success during this period.
In 2004, HAB Pharma expanded its manufacturing capabilities with a new facility in Dehradun. This marked the beginning of a series of expansions, enabling the production of a wide range of products including tablets, capsules, ointments, eye drops, and aerosol sprays. Their pharmaceutical aerosol sprays, like PAIN O JOINT and Tekomol Spray, gained recognition, with products like Sumo Spray for Alkem Laboratories adding to their industry reputation.
The inauguration of Signature Phytochemical Industries in 2016 underscored HAB Pharma’s commitment to growth and innovation. Since then, the company has maintained a robust compound annual growth rate (CAGR) of 30 percent, with revenues exceeding INR ₹ 600 crores as of March 2024.
NEWSLETTER
TRENDING ON PRO MFG
MORE FROM THE SECTION
